{"nctId":"NCT00867165","briefTitle":"Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","startDateStruct":{"date":"2009-05-21","type":"ACTUAL"},"conditions":["Primary Hypercholesterolemia"],"count":138,"armGroups":[{"label":"Ezetimibe","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ezetimibe","otherNames":["SCH 58235","MK-0653","Zetia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Each subject may be of either sex and of any race/ethnicity, and must be \\>=6 and \\<=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of \\>159mg/dL\n* Each subject's parent/guardian must be willing to give written informed consent on his/her behalf.\n\nExclusion Criteria:\n\nEach subject must not:\n\n* Have known hypersensitivity or any contraindication to ezetimibe.\n* Have use of any investigational drugs within 30 days of study entry.\n* Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.\n* Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing\n* Have known congenital cardiac disorder.\n* Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).\n* Be known to be human immunodeficiency virus (HIV) positive.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12","description":"Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \\[HDL-C\\] + triglyceride \\[TG\\]/5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.70","spread":null},{"groupId":"OG001","value":"-0.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Total Cholesterol (TC) at Week 12","description":"Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.74","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12","description":"Serum Apo B measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.66","spread":null},{"groupId":"OG001","value":"-1.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12","description":"Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null},{"groupId":"OG001","value":"1.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non-HDL-C at Week 12","description":"Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.47","spread":null},{"groupId":"OG001","value":"0.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Triglycerides (TG) at Week 12","description":"Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":null},{"groupId":"OG001","value":"8.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Week 2","description":"Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \\[HDL-C\\] + triglyceride \\[TG\\]/5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.75","spread":null},{"groupId":"OG001","value":"0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Week 4","description":"Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \\[HDL-C\\] + triglyceride \\[TG\\]/5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.93","spread":null},{"groupId":"OG001","value":"-2.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Week 8","description":"Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \\[HDL-C\\] + triglyceride \\[TG\\]/5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.22","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC at Week 2","description":"Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.69","spread":null},{"groupId":"OG001","value":"1.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC at Week 4","description":"Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.57","spread":null},{"groupId":"OG001","value":"-0.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC at Week 8","description":"Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.84","spread":null},{"groupId":"OG001","value":"0.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline HDL-C at Week 2","description":"Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline HDL-C at Week 4","description":"Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null},{"groupId":"OG001","value":"0.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline HDL-C at Week 8","description":"Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"-0.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non-HDL-C at Week 2","description":"Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.54","spread":null},{"groupId":"OG001","value":"1.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non-HDL-C at Week 4","description":"Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.94","spread":null},{"groupId":"OG001","value":"-0.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non-HDL-C at Week 8","description":"Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.41","spread":null},{"groupId":"OG001","value":"1.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TG at Week 2","description":"Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.90","spread":null},{"groupId":"OG001","value":"5.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TG at Week 4","description":"Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.54","spread":null},{"groupId":"OG001","value":"9.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TG at Week 8","description":"Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.99","spread":null},{"groupId":"OG001","value":"-1.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12","description":"Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null},{"groupId":"OG001","value":"3.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC:HDL-C Ratio at Week 2","description":"Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.21","spread":null},{"groupId":"OG001","value":"2.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC:HDL-C Ratio at Week 4","description":"Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.36","spread":null},{"groupId":"OG001","value":"1.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC:HDL-C Ratio at Week 8","description":"Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.07","spread":null},{"groupId":"OG001","value":"3.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in TC:HDL-C Ratio at Week 12","description":"Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.09","spread":null},{"groupId":"OG001","value":"1.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2","description":"Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.35","spread":null},{"groupId":"OG001","value":"1.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4","description":"Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.72","spread":null},{"groupId":"OG001","value":"-0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8","description":"Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.43","spread":null},{"groupId":"OG001","value":"2.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12","description":"Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.01","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12","description":"Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.16","spread":null},{"groupId":"OG001","value":"-2.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4","description":"Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":null},{"groupId":"OG001","value":"56.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12","description":"Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.35","spread":null},{"groupId":"OG001","value":"-7.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Sitosterol at Week 2","description":"Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.20","spread":null},{"groupId":"OG001","value":"-0.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Sitosterol at Week 4","description":"Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.82","spread":null},{"groupId":"OG001","value":"-0.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Sitosterol at Week 8","description":"Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.59","spread":null},{"groupId":"OG001","value":"-0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Sitosterol at Week 12","description":"Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.65","spread":null},{"groupId":"OG001","value":"2.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Campesterol at Week 2","description":"Plasma campesterol measured at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.87","spread":null},{"groupId":"OG001","value":"-4.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Campesterol at Week 4","description":"Plasma campesterol measured at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.27","spread":null},{"groupId":"OG001","value":"-4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Campesterol at Week 8","description":"Plasma campesterol measured at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.79","spread":null},{"groupId":"OG001","value":"-4.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Campesterol at Week 12","description":"Plasma campesterol measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.59","spread":null},{"groupId":"OG001","value":"-2.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Cholestanol at Week 2","description":"Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.44","spread":null},{"groupId":"OG001","value":"-7.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Cholestanol at Week 4","description":"Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.40","spread":null},{"groupId":"OG001","value":"-1.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Cholestanol at Week 8","description":"Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.19","spread":null},{"groupId":"OG001","value":"-0.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Cholestanol at Week 12","description":"Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.71","spread":null},{"groupId":"OG001","value":"3.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Lathosterol at Week 2","description":"Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.07","spread":null},{"groupId":"OG001","value":"14.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Lathosterol at Week 4","description":"Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.02","spread":null},{"groupId":"OG001","value":"6.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Lathosterol at Week 8","description":"Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.87","spread":null},{"groupId":"OG001","value":"-0.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Lathosterol at Week 12","description":"Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.62","spread":null},{"groupId":"OG001","value":"12.57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":92},"commonTop":["Nasopharyngitis","Headache","Abdominal pain","Influenza","Upper respiratory tract infection"]}}}